“Raise your batteries from the dead” is the mantra of Legends Business Group (Pinksheets: LGBS) for its Line of Zombie Chargers. The company is set to bring its new products to market in beta versions that are designed to showcase the prowess of the new charging systems, called the “Multi-Function Charger Controller,” or MFCC, and the “Restorer Charger,” or RC. Read More

Rotech Healthcare Inc. (OTCBB: ROHI) reported late Wednesday its financial results for the third quarter ended September 30, 2012, showing growth across key indicators and significant decreases in other revenue generators for the provider of home medical equipment and related products. Read More

AltiGen Communications, Inc. (OTCQX: ATGN) reported steeper losses Wednesday from the fourth quarter and fiscal years ended September 30, 2012, as the company booked a one-time, non-cash charge for excess inventory. Read More

Commenting on the October 25 approval by the European Commission for its gene therapy, Glybera®, Dutch biotech company uniQure said Monday it plans to start selling Glybera in Europe by mid-2013 and predicted a boom of similar therapies.  The EC approval marks Glybera as the first gene therapy to be approved in the Western world. Read More

Axesstel Inc. (OTCQB: AXST) Tuesday reported its earnings for the third quarter and nine months ended September 30.  Revenue for the quarter totaled $16.3 million; down from $17.1 million in the same quarter of 2011 for the provider of fixed wireless voice and broadband access solutions.  Net income significantly increased from $1.3 million, or 5 cents per diluted share, in Q3 2011 to $2.1 million, or 8 cents per diluted share, in the most recent quarter, due Read More

PacWest Equities, Inc. (Pinksheets: PWEID) said Monday that third quarter sales for its 100-percent-owned subsidiary PurGro Electronics increased by 430 percent as compared to sales from the year prior quarter.  Dollar amounts were not provided in the corporate statement.  Sales have been rising for three consecutive quarters, according to the company.

A pinksheet-listed company, PacWest does not submit filings to the Security and Exchange Commission and carries the skull and crossbones (Caveat Emptor, or “Buyer Beware”) moniker for limited information on the OTC Markets website. Read More

On the heels of a steady stream of corporate developments in October that showcased the promising data that continues to build regarding its MultiStem® cell therapy, Athersys, Inc. (NASDAQ: ATHX) announced Thursday morning that its subsidiary, ReGenesys BVBA, recently received the BioProcess International Award for the “Technical Application of the Decade” in Manufacturing for its use of an automated bioreactor system for the production of MultiStem. Read More

In the biotechnology world, the sun rises and set around the two key words “safety” and “efficacy.”  A serious safety concern resulted in Bristol-Myers Squibb (NYSE: BMY) voluntarily halting its ongoing Phase 2 study of BMS-986094, a drug in development as a new indication for hepatitis C as part of the drug maker’s quest for an all-oral regimen for hep C.  A patient who had received a 200 milligram dose of the nucleotide polymerase inhibitor, or “nuke,” suffered heart failure; causing Bristol to stop the trial and begin evaluating participants to determine Read More

An article from August 13 by Seeking Alpha contributor A. Jackson discussed the state of big pharma’s pipelines and the potential of Cellceutix (OTCBB: CTIX) anti-cancer drug, Kevetrin, as it enters clinical trials at Dana-Farber and Beth Israel Deaconess. More acutely, Jackson details the relationship between Pfizer and Cellceutix and why the smaller biotech could be a logical acquisition target for the world’s biggest drug maker. Read More

Alzheimer’s disease is deservedly receiving plenty of press recently.  Olympic commercials are being used to advertise the Alzheimer’s Association® “Walk to End Alzheimer’s®,” which will take place at 11 locations throughout Massachusetts and New Hampshire in September this year.  According to an article this week on the Genetic Engineering and Biotechnology’s website, more than 150 companies are working in the Alzheimer’s industry with in excess of 100 of those companies developing a drug for the horrific disease. Read More